Entrada Therapeutics (TRDA) Competitors $6.55 -0.21 (-3.11%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$6.54 0.00 (-0.08%) As of 07/11/2025 06:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TRDA vs. AMPH, WVE, AUPH, ARDX, ELVN, VERV, NAGE, DYN, CDTX, and COLLShould you be buying Entrada Therapeutics stock or one of its competitors? The main competitors of Entrada Therapeutics include Amphastar Pharmaceuticals (AMPH), WAVE Life Sciences (WVE), Aurinia Pharmaceuticals (AUPH), Ardelyx (ARDX), Enliven Therapeutics (ELVN), Verve Therapeutics (VERV), Niagen Bioscience (NAGE), Dyne Therapeutics (DYN), Cidara Therapeutics (CDTX), and Collegium Pharmaceutical (COLL). These companies are all part of the "pharmaceutical products" industry. Entrada Therapeutics vs. Its Competitors Amphastar Pharmaceuticals WAVE Life Sciences Aurinia Pharmaceuticals Ardelyx Enliven Therapeutics Verve Therapeutics Niagen Bioscience Dyne Therapeutics Cidara Therapeutics Collegium Pharmaceutical Entrada Therapeutics (NASDAQ:TRDA) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability. Do institutionals & insiders have more ownership in TRDA or AMPH? 86.4% of Entrada Therapeutics shares are owned by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. 8.1% of Entrada Therapeutics shares are owned by company insiders. Comparatively, 27.5% of Amphastar Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media favor TRDA or AMPH? In the previous week, Entrada Therapeutics had 6 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 9 mentions for Entrada Therapeutics and 3 mentions for Amphastar Pharmaceuticals. Amphastar Pharmaceuticals' average media sentiment score of 0.55 beat Entrada Therapeutics' score of 0.46 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Entrada Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Amphastar Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Which has more volatility and risk, TRDA or AMPH? Entrada Therapeutics has a beta of -0.11, suggesting that its share price is 111% less volatile than the S&P 500. Comparatively, Amphastar Pharmaceuticals has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500. Which has higher valuation and earnings, TRDA or AMPH? Amphastar Pharmaceuticals has higher revenue and earnings than Entrada Therapeutics. Amphastar Pharmaceuticals is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEntrada Therapeutics$210.78M1.18$65.63M$0.818.09Amphastar Pharmaceuticals$731.97M1.39$159.52M$2.767.85 Is TRDA or AMPH more profitable? Amphastar Pharmaceuticals has a net margin of 19.38% compared to Entrada Therapeutics' net margin of 14.39%. Amphastar Pharmaceuticals' return on equity of 22.20% beat Entrada Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Entrada Therapeutics14.39% 5.84% 4.61% Amphastar Pharmaceuticals 19.38%22.20%10.40% Do analysts recommend TRDA or AMPH? Entrada Therapeutics currently has a consensus target price of $25.67, suggesting a potential upside of 291.86%. Amphastar Pharmaceuticals has a consensus target price of $32.33, suggesting a potential upside of 49.28%. Given Entrada Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Entrada Therapeutics is more favorable than Amphastar Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entrada Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Amphastar Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25 SummaryAmphastar Pharmaceuticals beats Entrada Therapeutics on 10 of the 17 factors compared between the two stocks. Get Entrada Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRDA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TRDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRDA vs. The Competition Export to ExcelMetricEntrada TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$248.59M$2.94B$5.56B$9.11BDividend YieldN/A2.42%5.06%4.01%P/E Ratio8.0920.8528.2320.27Price / Sales1.18298.79434.20100.92Price / Cash4.1342.1137.1257.67Price / Book0.577.638.045.49Net Income$65.63M-$55.05M$3.19B$250.45M7 Day Performance-9.47%8.43%3.62%4.78%1 Month Performance-13.70%8.14%5.98%9.58%1 Year Performance-61.81%1.62%29.39%16.41% Entrada Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRDAEntrada Therapeutics3.2263 of 5 stars$6.55-3.1%$25.67+291.9%-61.8%$248.59M$210.78M8.09110News CoverageInsider TradeAMPHAmphastar Pharmaceuticals4.3319 of 5 stars$22.86-1.5%$32.33+41.4%-44.0%$1.09B$731.97M8.282,028WVEWAVE Life Sciences4.5498 of 5 stars$7.06+1.6%$20.50+190.4%+37.0%$1.08B$108.30M-8.40240AUPHAurinia Pharmaceuticals3.0526 of 5 stars$7.47-1.6%$11.50+53.9%+56.9%$1.03B$235.13M26.68300Positive NewsARDXArdelyx4.1322 of 5 stars$4.35+1.9%$10.89+150.3%-23.8%$1.02B$333.61M-19.7790Analyst RevisionELVNEnliven Therapeutics2.822 of 5 stars$19.59-5.5%$41.20+110.3%-9.3%$1.02BN/A-10.2050Insider TradeVERVVerve Therapeutics3.0659 of 5 stars$11.16-1.1%$14.57+30.6%+63.9%$1.01B$59.61M-5.29110NAGENiagen Bioscience1.3498 of 5 stars$12.44-2.1%$19.50+56.8%+333.0%$1.00B$99.60M73.18120DYNDyne Therapeutics3.4007 of 5 stars$8.18-6.6%$41.13+402.8%-79.2%$995.72MN/A-2.28100Analyst ForecastHigh Trading VolumeCDTXCidara Therapeutics4.1382 of 5 stars$48.30-1.0%$57.14+18.3%+340.2%$983.59M$1.27M-1.6490Positive NewsAnalyst ForecastGap UpHigh Trading VolumeCOLLCollegium Pharmaceutical4.2136 of 5 stars$30.90+1.8%$43.75+41.6%+2.3%$975.20M$631.45M25.33210Buyback Announcement Related Companies and Tools Related Companies Amphastar Pharmaceuticals Alternatives WAVE Life Sciences Alternatives Aurinia Pharmaceuticals Alternatives Ardelyx Alternatives Enliven Therapeutics Alternatives Verve Therapeutics Alternatives Niagen Bioscience Alternatives Dyne Therapeutics Alternatives Cidara Therapeutics Alternatives Collegium Pharmaceutical Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TRDA) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entrada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entrada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
